Dexton

Each 1 mL contains Dexamethasone sodium phosphate equivalent to Dexamethasone phosphate 4 mg.

Intramuscular or intravenous administration: Allergic states: For control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment; seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis, atopic dermatitis, serum sickness, drug hypersensitivity reactions; acute noninfectious laryngeal edema, urticarial transfusion reactions.
Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus or acute rheumatic carditis.
Dermatologic diseases: Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; exfoliative erythroderma; mycosis fungoides; severe psoriasis; severe seborrheic dermatitis.
Edematous states: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that because of systemic lupus erythematosus.
Endocrine disorders: Primary, secondary, or acute adrenocortical insufficiency (hydrocortisone or cortisone is the first choice); preoperatively and in the event of serious trauma or illness, in adrenal insufficiency or when adrenocortical reserve is doubtful; septic shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected; congenital adrenal hyperplasia; nonsuppurative thyroiditis; hypercalcemia associated with cancer.
Gastrointestinal diseases: To tide the patient over a critical period of the disease in ulcerative colitis or regional enteritis.
Hematologic disorders: Immune thrombocytopenia in adults; secondary thrombocytopenia in adults (select cases); acquired (autoimmune) hemolytic anemia; pure red cell aplasia; congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia).
Neoplastic diseases: For palliative management of leukemias and lymphomas in adults and acute leukemia of childhood.
Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic diseases: In the severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis; keratitis; allergic corneal marginal ulcers; herpes zoster ophthalmicus; iritis and iridocyclitis; chorioretinitis; anterior segment inflammation; diffuse posterior uveitis and choroiditis; optic neuritis; sympathetic ophthalmia; temporal arteritis; uveitis; ocular inflammatory conditions unresponsive to topical corticosteroids.
Respiratory diseases: Symptomatic sarcoidosis; Loeffler syndrome not manageable by other means; berylliosis; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy; aspiration pneumonitis; idiopathic eosinophilic pneumonias.
Rheumatic disorders: For use as adjunctive therapy for short-term administration in psoriatic arthritis, rheumatoid arthritis (RA), juvenile RA, ankylosing spondylitis, acute and subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis, posttraumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis; treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
Intra-articular or soft tissue injection: For use as adjunctive therapy for short-term administration in synovitis or osteoarthritis, rheumatoid arthritis (RA), acute or subacute bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis and post-traumatic osteoarthritis.
Intralesional injection: Keloids; localized hypertrophic infiltrated, inflammatory lesions of lichen planus, psoriatic plaques, granuloma annulare and lichen simplex chronicus (neurodermatitis); discoid lupus erythematosus; necrobiosis lipoidica diabeticorum; alopecia areata, cystic tumors of an aponeurosis or tendon (ganglia).

Adults Dosing: Intramuscular or intravenous administration: Dose depend upon condition being treated and response of patient and then decrease in small increments at appropriate interval until the lowest dose that maintains a favorable response is reached. (See Table 1.)

Click on icon to see table/diagram/image

Intra-articular or soft tissue injection: See Table 2.

Click on icon to see table/diagram/image

Intralesional injection: See Table 3.

Click on icon to see table/diagram/image

Pediatric Dosing: Corticosteroids cause growth retardation in infancy, childhood and adolescence, which may be irreversible. Treatment should be limited to the minimum dosage for the shortest possible time. In order to minimize suppression of the hypothalamic pituitary-adrenal axis and growth retardation, treatment should be limited, where possible, to a single dose on alternate days.
Growth and development of infants and children on prolonged corticosteroid therapy should be carefully monitored.
Dosage requirements are variable and may have to be changed according to individual need. Usually 0.2 mg/kg-0.4 mg/kg (0.05 mL/kg-0.1 mL/kg) of body weight daily.
Geriatrics dosing: Use cautiously in the elderly in the smallest possible dose.
Dosage in renal impairments: No specific dosage adjustment is necessary, use with caution in renal impairment patients.
Supplemental dose is not necessary in hemodialysis or peritoneal dialysis.
Dosage in hepatic impairments: The effect of baseline hepatic impairment on the pharmacokinetics of the drug has not been studied. Use with caution in patient with hepatic impairment.

Must not use in patients with ocular herpes simplex, severe psychoneurosis, tuberculosis.
Hypersensitivity to dexamethasone or any component of the formulation.
Systemic fungal infection.

Contraindicated in patient with hypersensitivity to this medicine.
Contraindicated in patient with disseminated fungal infections, unless necessary.
Use with caution in patient with peptic or duodenal ulcer, diabetes mellitus, tuberculosis and viral infections.

Special precautions for disposal and other handling: The product should only be used when the solution is clear and particle free.
For 1 mL ampoule and 2 mL vial, discard any unused solution after use.

Store below 30°C.

Corticosteroid Hormones

H02AB02 - dexamethasone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.

S